2012-13409. New Animal Drugs; Change of Sponsor's Name  

  • Start Preamble

    AGENCY:

    Food and Drug Administration, HHS.

    ACTION:

    Final rule.

    SUMMARY:

    The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect a change of sponsor's name from Novopharm Ltd. to Teva Canada Ltd.

    DATES:

    This rule is effective June 4, 2012.

    Start Further Info

    FOR FURTHER INFORMATION CONTACT:

    Steven D. Vaughn, Center for Veterinary Medicine (HFV-100), Food and Drug Administration, 7520 Standish Pl., Rockville, MD 20855, 240-276-8300, email: steven.vaughn@fda.hhs.gov.

    End Further Info End Preamble Start Supplemental Information

    SUPPLEMENTARY INFORMATION:

    Novopharm Ltd., 30 Novopharm Ct., Toronto, Ontario, Canada M1B 2K9 has informed FDA of a change of name to Teva Canada Ltd. Accordingly, the Agency is amending the regulations in 21 CFR 510.600(c) to reflect these changes.

    This rule does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a rule of “particular applicability.” Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808.

    Start List of Subjects

    List of Subjects in 21 CFR Part 510

    • Administrative practice and procedure
    • Animal drugs
    • Labeling
    • Reporting and recordkeeping requirements
    End List of Subjects

    Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR part 510 is amended as follows:

    Start Part

    PART 510—NEW ANIMAL DRUGS

    End Part Start Amendment Part

    1. The authority citation for 21 CFR part 510 continues to read as follows:

    End Amendment Part Start Authority

    Start Printed Page 32898 Authority: 21 U.S.C. 321, 331, 351, 352, 353, 360b, 371, 379e.

    End Authority Start Amendment Part

    2. In § 510.600, in the table in paragraph (c)(1), remove the entry for “Novopharm Ltd.” and alphabetically add a new entry for “Teva Canada Ltd.”; and in the table in paragraph (c)(2), revise the entry for “043806” to read as follows:

    End Amendment Part
    Names, addresses, and drug labeler codes of sponsors of approved applications.
    * * * * *

    (c) * * *

    (1) * * *

    Firm name and addressDrug labeler code
    *    *    *    *    *
    Teva Canada Ltd., 30 Novopharm Ct., Toronto, Ontario, Canada M1B 2K9043806
    *    *    *    *    *

    (2) * * *

    Drug labeler codeFirm name and address
    *    *    *    *    *
    043806Teva Canada Ltd., 30 Novopharm Ct., Toronto, Ontario, Canada M1B 2K9.
    *    *    *    *    *
    Start Signature

    Dated: May 29, 2012.

    Bernadette Dunham,

    Director, Center for Veterinary Medicine.

    End Signature End Supplemental Information

    [FR Doc. 2012-13409 Filed 6-1-12; 8:45 am]

    BILLING CODE 4160-01-P